替格列汀加速顺铂诱导急性肾损伤恢复的机制研究
该研究在大鼠顺铂诱导的急性肾损伤(AKI)模型中,口服二肽基肽酶-4(DPP-4)抑制剂替格列汀(TG)10 mg/kg/天,从顺铂注射前或第5天开始,发现TG可减轻AKI并加速肾功能恢复。体外实验显示TG直接促进原代肾小管上皮细胞增殖,机制涉及抑制炎症、促进M2巨噬细胞极化及抑制CXCL12降解。
要点
- 替格列汀可加速顺铂诱导的AKI大鼠肾小管再生和功能恢复。
- 机制包括抗炎、促进M2巨噬细胞极化及抑制CXCL12降解。
- 体外实验证实替格列汀直接促进肾小管上皮细胞增殖。
核心结论
- DPP-4抑制剂替格列汀可通过抗炎作用和可能抑制CXCL12分解来加速毒性AKI的肾小管再生和功能恢复。
研究设计与样本
- 体内实验:大鼠静脉注射顺铂5 mg/kg诱导AKI,口服替格列汀10 mg/kg每日一次,从顺铂注射前或注射后第5天开始。
- 体外实验:分离小鼠肾小管细胞,采用MTT法、细胞周期分析和细胞计数评估增殖,MTT法或LDH法分析细胞活力。
主要发现
- 体内实验发现替格列汀减轻顺铂诱导的AKI,并通过促进近端小管存活上皮细胞增殖加速损伤后肾脏恢复。
- 替格列汀抑制肾脏内肿瘤坏死因子-α表达,并诱导巨噬细胞向抗炎M2表型极化。
- 体外实验显示替格列汀直接加速原代肾小管上皮细胞增殖。
- 体外筛选DPP-4底物趋化因子发现CXCL12为促有丝分裂因子,可加速增殖并抑制顺铂暴露后原代肾小管上皮细胞死亡。
- CXCR4拮抗可消除替格列汀的促增殖效应。
临床怎么用
- DPP-4抑制剂可能限制顺铂肾毒性并改善癌症患者肾功能,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin is an effective chemotherapeutic agent. However, acute kidney injury (AKI) and subsequent kidney function decline limits its use. Dipeptidyl peptidase-4 (DPP-4) inhibitor has been reported to attenuate kidney injury in some in vivo models, but the mechanisms-of-action in tubule recovery upon AKI remain speculative. We hypothesized that DPP-4 inhibitor teneligliptin (TG) can facilitate kidney recovery after cisplatin-induced AKI. METHODS: In in vivo experiment, AKI was induced in rats by injecting 5 mg/kg of cisplatin intravenously. Oral administration of 10 mg/kg of TG, once a day, was started just before injecting cisplatin or from Day 5 after cisplatin injection. In an in vitro experiment, proliferation of isolated murine tubular cells was evaluated with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay, cell cycle analysis and cell counting. Cell viability was analysed by MTT assay or lactate dehydrogenase (LDH) assay. RESULTS: In in vivo experiments, we found that TG attenuates cisplatin-induced AKI and accelerates kidney recovery after the injury by promoting the proliferation of surviving epithelial cells of the proximal tubule. TG also suppressed intrarenal tumour necrosis factor-α expression, and induced macrophage polarization towards the anti-inflammatory M2 phenotype, both indirectly endorsing tubule recovery upon cisplatin injury. In in vitro experiments, TG directly accelerated the proliferation of primary tubular epithelial cells. Systematic screening of the DPP-4 substrate chemokines in vitro identified CXC chemokine ligand (CXCL)-12 as a promoted mitogenic factor. CXCL12 not only accelerated proliferation but also inhibited cell death of primary tubular epithelial cells after cisplatin exposure. CXC chemokine receptor (CXCR)-4 antagonism abolished the proliferative effect of TG. CONCLUSIONS: The DPP-4 inhibitor TG can accelerate tubule regeneration and functional recovery from toxic AKI via an anti-inflammatory effect and probably via inhibition of CXCL12 breakdown. Hence, DPP-4 inhibitors may limit cisplatin-induced nephrotoxicity and improve kidney function in cancer patients.
引用
- Iwakura T, Zhao Z, Marschner JA, et al. Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration. Nephrol Dial Transplant. 2019. PMID: 30624740. doi:10.1093/ndt/gfy397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。